Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...

Beauty manifests differently across the globe’s greatest cities, from Venice’s impossible architecture floating on lagoon ...

Participants were presented with polyphonic music made of two monophonic streams (PolyOrig condition), with control stimuli where the average pi ...

Secretary of the Ministry of Ayush, Padma Shri Vaidya Rajesh Kotecha, explains how Ayurveda is being integrated into India’s ...

Endovascular Stent Grafts Market to Reach $1.76 billion by 2032, Driven by Aging Populations and Advances in Device Durability Request for customizatio  The global Endovascular Stent Grafts ...

Louisiana hides a secret that rivals any European garden tour, and you don’t need your passport to find it. The New Orleans Botanical Garden at City Park stands as a 12-acre masterpiece where Spanish ...

The Conservatory gleams in the Louisiana sunshine, its glass panels creating a cathedral-like atmosphere for the tropical specimens housed within. Inside this climate-controlled haven, plants from ...

Activation of the complement cascade of proteases has been linked to autoimmune and kidney diseases, including systemic lupus erythematosus (SLE). Here, optimization of a workflow for protease ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes included scores on the Myasthenia-Gravis Activities of Daily Living (MG-ADL) ...